Georgiana Toma: From Cytoreduction to Vascular Protection in Essential Thrombocythemia
Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:
“To my colleagues in internal medicine and neurology
We have all managed patients with ‘controlled’ platelet counts who still suffer from devastating recurrent strokes or systemic thrombotic events.
The results of the SURPASS-ET study (published in The Lancet Haematology, 2026) change the conversation from simple cytoreduction to vascular protection and disease modification.
Ropeginterferon alfa-2b
For our patients resistant to hydroxyurea, the comparison between Ropeginterferon alfa-2b and Anagrelide reveals a massive shift in the safety-efficacy balance:
- Vascular Risk: Complications (including cerebral infarction) were significantly lower with Ropeginterferon compared to Anagrelide.
- Safety Profile: Half the rate of Serious Adverse Events (14 percent versus 30 percent).
- Durable Response: A staggering 43 percent durable response at 12 months versus only 6 percent for anagrelide (p less than 0.0001).
Why this matters for your practice:
- Ropeginterferon significantly reduces the JAK2 (V617F) allelic burden. This suggests we can actually prevent the long-term transformation into Myelofibrosis or Acute Leukemia—something traditional therapies struggled to achieve.
- Neurological Protection: For Neurologists, this offers a potent tool to reduce the risk of cerebral infarction and hemorrhage in high-risk MPN patients.
- Fewer Side Effects: Better tolerability means higher compliance and fewer hospitalizations for drug-related complications.
The Bottom Line
We are moving toward a new standard where molecular remission is the goal.
By targeting the underlying biology of Myeloproliferative Neoplasms, we aren’t just treating a lab value; we are protecting our patients’ vascular future.”
Title: Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
Authors: Ruben Mesa, Harinder Gill, Lei Zhang, Jie Jin, Keita Kirito, Norio Komatsu, Albert Qin, Zhijian Xiao, Tsewang Tashi, Kazuya Shimoda, Kohshi Ohishi, Suning Chen, Xuelan Zuo, Shuichi Shirane, Yu Hu, Sujiang Zhang, Yi Wang, Katsuto Takenaka, Michiko Ichii, Na Xu, Lee-Yung Shih, Ken-Hong Lim, Sung-Eun Lee, Sung Hwa Bae, Winnie Z Y Teo, Dawn Maze, Stephen T Oh, Prithviraj Bose, Toshiaki Sato, Zagrijtschuk, Sheena Lin, Weichung Joe Shih, John Mascarenhas, Lucia Masarova
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal